Sanofi ADR (SNY)
Sanofi ADR is a depositary receipt listed on NASDAQ that represents common stock of Sanofi, the pharmaceutical group headquartered in Paris, France. Sanofi develops, manufactures, and markets therapeutic solutions across several areas, including immunology and inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio includes pediatric, respiratory syncytial virus, influenza, COVID-19, meningitis, travel, and endemic vaccines, along with combination products covering diseases such as diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B. The company also pursues research and development through collaborations with partners such as Exscientia, ABL Bio, Innate Pharma, Atomwise, Insilico Medicine, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, Adagene, Scribe Therapeutics, Teva Pharmaceuticals, and Provention Bio. Formerly known as Sanofi-Aventis, the company adopted the Sanofi name in 2011.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SNY
|
$64.39
|
46.8% Upside
|
Undervalued
|
$55.06
|
25.6% Upside
|
Undervalued
|
Great
|
—
|
—
|
1.7648
|
4.0%
|
July 30, 2026
|
19.1x
|
1.3x
|
1.9x
|
105.6 B
|
123.8 B
|
17.7%
|
90.3%
|
5.8
|
63.2%
|
177.6%
|
